Dox-SL data

LTIZ reported on 133 patients from an ongoing European and Australian Phase II open-label study of 247 patients with moderate to severe KS.

After six cycles of Dox-SL, 3 patients (2.3 percent) achieved a complete response and 81 (60.9 percent) had partial responses. In addition, 39 patients (28.6 percent) had stable disease and 11 patients (8.3 percent) had progression of disease. ...